Akebia Therapeutics, Inc. (AKBA)
A
Pipeline Grade
Financial Position (from SEC Filings)
$164.4M
Cash & Equivalents
$21.2M
Quarterly Burn Rate
23 mo
Est. Cash Runway
$276M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
VADADUSTAT
VAFSEO |
APPROVED | Acute Respiratory Distress Syndrome, Anemia, Anemia Associated With Chronic Kidney Disease, Anemia Associated With Chronic Kidney Disease (CKD), Anemia of Chronic Kidney Disease, Anemia, Iron Deficiency, Cardiovascular, Chronic Kidney Disease, Coronavirus Infection, Dialysis-Dependent Chronic Kidney Disease, Disease Progression, Drug Interaction Potentiation, End Stage Renal Disease, Focal Segmental Glomerulosclerosis, Healthy, Healthy Volunteers, Heart Failure With Preserved Ejection Fraction, Hepatic Impairment, Hyperphosphatemia, Iron, Kidney Disease, Non-Dialysis-Dependent Chronic Kidney Disease, Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury, Pharmacokinetics, Renal Anemia, Renal Insufficiency, Renal Insufficiency, Chronic, Type 2 Diabetes Mellitus With Diabetic Nephropathy |
Upcoming Catalysts
No upcoming catalysts detected for this company.